NCT03855917View on ClinicalTrials.gov

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir 400mg [Sovaldi]

Four weeks.

DRUG

Glecaprevir/pibrentasvir (300mg/120mg)

Four weeks.

Trial Locations (3)

2010

RECRUITING

St Vincent's Hospital, Darlinghurst

2148

RECRUITING

Blacktown Mt Druitt Hospital, Sydney

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
lead

Kirby Institute

OTHER_GOV